Refining pharmacogenetic research in schizophrenia : Control for patient-related variables

doi:10.1002/ddr.10295

淡江大學機構典藏 > 商管學院 > 企業管理學系暨研究所 > 期刊論文 > Item 987654321/41222

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/41222

Title:	Refining pharmacogenetic research in schizophrenia : Control for patient-related variables
Authors:	Chang, Yue-cune
Contributors:	淡江大學數學學系
Keywords:	5-HT2A;polymorphism;schizophrenia;atypical antipsychotics;negative symptoms
Date:	2003-09-16
Issue Date:	2010-01-28 07:00:04 (UTC+8)
Publisher:	Wiley-Blackwell
Abstract:	There is strong evidence to suggest that genetic variation plays an important role in inter-individual differences in medication response and toxicity. Most of the previous pharmacogenetic studies, however, cannot be reconfirmed. Of note, drug efficacy or side effects depend not only on genetic factors but also on nongenetic factors, such as illness duration, past treatment history, and drug dosage or blood concentration. However, most pharmacogeneticists did not consider or control the possible impact of the nongenetic factors. Schizophrenia is a severe neuropsychiatric disorder with a polygenic mode of inheritance that is also governed by nongenetic factors. Schizophrenia's symptoms are principally subdivided into two subtypes, positive and negative. The positive symptoms include delusions and hallucinations; the negative symptoms, blunted affect and social withdrawal. Atypical antipsychotics are usually superior in the treatment of negative symptoms than typical agents. Although atypical agents are becoming the mainstay for schizophrenia treatment, what makes an antipsychotic “atypical” remains unclear. One of our recent studies have simultaneously evaluated the effects of genetic and nongenetic determinants on the efficacy of risperidone (a widely used atypical antipsychotic agent). We found that 5-HT2A receptor 102-T/C polymorphism could predict clinical response (mainly for negative symptoms rather than positive symptoms) in schizophrenia. Among nongenetic factors, fewer previous hospitalizations and higher risperidone dosage also predicted better treatment response after control for the 102-T/C polymorphism and other confounders. It is hoped that this novel study model could revolutionize future research in pharmacogenetics or other fields of genetics. Drug Dev. Res. 60:164–171, 2003. © 2003 Wiley-Liss, Inc.
Relation:	Drug Development Research 60(2), 　p.164-171
DOI:	10.1002/ddr.10295
Appears in Collections:	[企業管理學系暨研究所] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	143	View/Open
Refining pharmacogenetic research in schizophrenia Control for patient-related variables.pdf		89Kb	Adobe PDF	2	View/Open

Loading...